BIOASTER announces today, the initiation of a collaborative project aiming at improving the safety and immunogenicity of adjuvants included in the composition of new candidate vaccines. MOSAIC (MOlecular Signatures of Adjuvanted vaccIne Candidates) is a unique opportunity for BIOASTER to capitalize on its translational high-throughput omics pipelines relying on integrated transcriptomics, metabolomics and high-dimensional cell phenotyping, to study the molecular signature of the adjuvanted vaccine candidates within and across species.
MOSAIC will rely on several pre-clinical experimental species and a dedicated clinical trial to decipher adjuvant mode of action. This project is a unique opportunity to bridge cellular and molecular adjuvant specific signatures across species in order to better define their predictive capacities for human vaccine development. The success of the project will rely on a robust bioinformatics infrastructure able to host massive omics data and the development of innovative approaches to achieve advanced multi-omics data integration.
The complete release here.